A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Phase 3

Completed

• Conditions: Hyperlipidemia

• Registration Number: NCT00136942
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-04
• Study First Submitted: 2005-08-25
• Study First Submitted QC: 2005-08-25
• Study First Posted: 2005-08-29
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-17
• Last Update Posted: 2021-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 370

Inclusion Criteria

• Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
• LDL-C < 6.0 mmol/l
• Triglyceride level < 5.0 mmol/l.

Exclusion Criteria

• Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary Outcome Measures

Name	Time	Method
The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇨🇭 Zuerich, ZH, Switzerland